Patient Advocacy. Each Nurse has the responsibility to act as a patient advocate in accordance with the Nurse Practice Act. If in this role a Nurse reasonably believes it necessary to call attention to a condition which she/he also reasonably believes compromises required standards of care, the Nurse shall report it to her/his immediate supervisor. The Hospital will investigate the condition and will take any appropriate remedial action it finds necessary. No Nurse submitting such a report will be disciplined for so doing. A Nurse or the Association may grieve or elect to arbitrate under Article XX any disciplinary action taken against a Nurse(s) for making such a report. Any other questions or disputes of any kind relating to this paragraph, including where a Nurse believes that punitive action other than disciplinary action has occurred because of making a report (such as changes in assignments, etc.) shall be resolved by (1) The Nurse(s) discussing their concern and the pertinent facts with their immediate supervisor, (2) if not resolved, the Nurse(s) will submit their concern in writing, along with any pertinent facts to their Director and to the Association simultaneously, who will then meet and discuss it, and (3) if the question remains unresolved, it shall be referred to the Chief Nursing Officer who will place it on the agenda for joint discussion at the Coordinating Council. No questions or disputes of any kind relating to this paragraph shall be subject to the Grievance and Arbitration provision of Article XX, except a Nurse who perceives that disciplinary or severe, unresolved punitive action is being taken against her/him because of having made a report, has access to the provisions of the Grievance and Arbitration Procedure (Article
Patient Advocacy. The Joint Development Subcommittee shall be responsible for the oversight and control of the conduct of all global patient advocacy activities with respect to the Products in the Territory, including sponsorship of, and presentations and other disclosures made to, patient advocacy groups by a Party with respect to the Products in the Territory; provided, however, that (i) GSK shall be responsible for and control the conduct of all patient advocacy activities with respect to the Products that relate solely to the GSK Territory (including ****** - Material has been omitted and filed separately with the Commission. activities conducted in the GSK Territory with respect to a patient advocacy group located solely in the GSK Territory) and (ii) Amicus shall be responsible for and control the conduct of all patient advocacy activities with respect to the Products that relate solely to the Amicus Territory (including activities conducted in the Amicus Territory with respect to a patient advocacy group located solely in the Amicus Territory). For the avoidance of doubt, any decisions of a Party with respect to the conduct of patient advocacy activities with respect to the Products that relate solely to such Party’s respective territory (including such Party’s determination that such activities relate solely to such Party’s respective territory) shall be final and shall not be subject to the terms of Sections 4.2.3(c), 4.1.5(a) or 16.2.
Patient Advocacy. Provider shall not be disciplined by IGS for acting as an advocate for the patient in seeking appropriate, medically necessary health services or for filing a complaint or appeal pursuant to the terms of the Agreement or as permitted by applicable law. Provider shall have the right to communicate openly with a patient about all diagnostic and treatment options
